Thomas Steger‐Hartmann

ORCID: 0000-0003-4258-3008 · 1 paper in corpus

rct 2023

Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis

Drugs in R&D ·doi:10.1007/s40268-023-00427-5

INTRODUCTION: BAY1128688 is a selective inhibitor of aldo-keto reductase family 1 member C3 (AKR1C3), an enzyme implicated in the pathology of endometriosis and other disorders. In vivo animal studies suggested a potential therapeutic appli…